These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 27690667)

  • 1. Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors.
    Hong JH; Kwon YS; Kim IY
    Expert Opin Drug Metab Toxicol; 2017 Feb; 13(2):183-192. PubMed ID: 27690667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction.
    Ventimiglia E; Capogrosso P; Montorsi F; Salonia A
    Expert Opin Drug Saf; 2016; 15(2):141-52. PubMed ID: 26752541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction.
    Yafi FA; Sharlip ID; Becher EF
    Sex Med Rev; 2018 Apr; 6(2):242-252. PubMed ID: 28923561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Avanafil - a further step to tailoring patient needs and expectations.
    Boeri L; Capogrosso P; Ventimiglia E; Serino A; La Croce G; Russo A; Damiano R; Montorsi F; Salonia A
    Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1171-81. PubMed ID: 27232892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety and efficacy of Avanafil, a new 2(nd) generation PDE5i: comprehensive review and meta-analysis.
    Corona G; Rastrelli G; Burri A; Jannini EA; Maggi M
    Expert Opin Drug Saf; 2016; 15(2):237-47. PubMed ID: 26646748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis.
    Chen L; Staubli SE; Schneider MP; Kessels AG; Ivic S; Bachmann LM; Kessler TM
    Eur Urol; 2015 Oct; 68(4):674-80. PubMed ID: 25817916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update on the drug safety of treating erectile dysfunction.
    Gul M; Serefoglu EC
    Expert Opin Drug Saf; 2019 Oct; 18(10):965-975. PubMed ID: 31433252
    [No Abstract]   [Full Text] [Related]  

  • 8. How to evaluate the efficacy of the phosphodiesterase type 5 inhibitors.
    Jannini EA; DeRogatis LR; Chung E; Brock GB
    J Sex Med; 2012 Jan; 9(1):26-33. PubMed ID: 22221307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Avanafil for the treatment of erectile dysfunction.
    Zurawin JL; Stewart CA; Anaissie JE; Yafi FA; Hellstrom WJ
    Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1163-70. PubMed ID: 27416913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails.
    Lee M; Sharifi R
    Drugs Aging; 2018 Mar; 35(3):175-187. PubMed ID: 29464656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Genetic Polymorphism on the Response to PDE5 Inhibitors in Patients With Erectile Dysfunction: A Systematic Review and a Critical Appraisal.
    Mostafa T; Hassan A; Alghobary MF; Abdelrahman SH
    Sex Med Rev; 2020 Oct; 8(4):573-585. PubMed ID: 32636154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work?
    Pofi R; Gianfrilli D; Badagliacca R; Di Dato C; Venneri MA; Giannetta E
    J Endocrinol Invest; 2016 Feb; 39(2):131-42. PubMed ID: 26142740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An overview of conventional and investigational phosphodiesterase 5 inhibitors for treating erectile dysfunction and other conditions.
    Ismail EA; El-Sakka AI
    Expert Opin Investig Drugs; 2024 Sep; 33(9):925-938. PubMed ID: 39096237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in pharmacotherapy for erectile dysfunction and associated cardiac impact.
    Voznesensky I; DeLay KJ; Hellstrom WJ
    Expert Opin Pharmacother; 2016 Dec; 17(17):2281-2289. PubMed ID: 27677349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral phosphodiesterase type 5 inhibitors and male reproductive potential: an overview.
    Mostafa T; Alghobary M; Hanafy NS; Abosief A
    Sex Med Rev; 2023 Jun; 11(3):240-252. PubMed ID: 36990971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SOP conservative (medical and mechanical) treatment of erectile dysfunction.
    Porst H; Burnett A; Brock G; Ghanem H; Giuliano F; Glina S; Hellstrom W; Martin-Morales A; Salonia A; Sharlip I;
    J Sex Med; 2013 Jan; 10(1):130-71. PubMed ID: 23343170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alprostadil for the treatment of impotence.
    Hanchanale V; Eardley I
    Expert Opin Pharmacother; 2014 Feb; 15(3):421-8. PubMed ID: 24369066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple PDE5Is use as a marker of decreased overall men's health: A real-life study.
    Oreggia D; Ventimiglia E; Capogrosso P; Boeri L; Cazzaniga W; Pederzoli F; Chierigo F; Dehò F; Montorsi F; Salonia A
    PLoS One; 2018; 13(8):e0201601. PubMed ID: 30096166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Avanafil for erectile dysfunction.
    Kyle JA; Brown DA; Hill JK
    Ann Pharmacother; 2013 Oct; 47(10):1312-20. PubMed ID: 24259695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erectile Dysfunction Medications and Treatment for Cardiometabolic Risk Factors: A Pharmacoepidemiologic Study.
    Skeldon SC; Cheng L; Morgan SG; Detsky AS; Goldenberg SL; Law MR
    J Sex Med; 2017 Dec; 14(12):1597-1605. PubMed ID: 29198514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.